Grifols stock declined after Morgan Stanley revised its view on the Spanish healthcare company, citing a less certain path for medium-term revenue growth despite ongoing strength in profitability metrics.
The broker changed its rating on the shares to Equal-weight from Overweight and reduced its price target to €11 from €14. By 06:12 ET in U.S. premarket trading the shares were down about 1.6%.
Analyst rationale and forecasts
The downgrade follows Grifols' fiscal 2025 results and reflects Morgan Stanley's reduced expectations for growth over the coming years. The bank now models revenue growth of around 3% in constant currency for 2026 and forecasts adjusted EBITDA of €1.93 billion for the year, which it says equates to roughly 8% growth.
Analysts led by Thibault Boutherin pointed out that declines in certain product areas are central to the dimmer sales outlook, even as margins and cash generation remain encouraging.
Product-specific headwinds
Morgan Stanley highlighted pressure in the albumin business as a key drag on growth prospects, especially in China. The bank said the China albumin market has faced weaker demand and pricing pressure since mid-2025 due to government restrictions on hospital reimbursement.
Analysts wrote that they expect those headwinds on albumin in China to persist into the first half of 2026 with limited scope for recovery beyond that period. They also described the outlook for alpha-1 proteins as uncertain.
Profitability focus and volume strategy
The analysts noted that Grifols' management appears to be prioritizing profitability over volume expansion. That stance, they said, is likely to constrain top-line growth in the near term as the company trades volume gains for margin protection.
Part of the expected moderate revenue expansion for 2026 reflects a voluntary slowdown in immunoglobulin (IG) volume growth while the company reallocates supply toward higher-value markets. Morgan Stanley summarized this approach by saying a decline in China albumin sales and slower alpha-1 growth are prompting Grifols to limit IG volume growth in 2026 to protect margins.
Cash flow, valuation and competitive risk
Despite the revenue uncertainties, Morgan Stanley emphasized strong adjusted EBITDA and free cash flow momentum. The bank expects free cash flow of between €500 million and €575 million in 2026, driven by margin expansion.
However, analysts cautioned that margin improvements on their own may not be sufficient to sustain long-term growth if revenue momentum weakens. They also flagged potential competition in the alpha-1 therapy space as an additional source of uncertainty, noting that a possible filing of Sanofi's recombinant alpha-1 therapy would represent a key binary risk for the franchise.
On valuation, Morgan Stanley observed that Grifols' shares trade at about nine times next-twelve-month EV/EBITDA, which the bank regards as relatively attractive. Nevertheless, the combination of uncertain revenue growth and competitive threats led the firm to adopt a more neutral stance on the stock.
Implications
The downgrade underscores a tension in Grifols' near-term profile: robust profitability and free cash flow forecasts on one side, and limited revenue visibility driven by product- and market-specific headwinds on the other. Investors will likely watch developments in China albumin demand, alpha-1 competition, and management's execution of its margin-first strategy for signs of a clearer growth trajectory.